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Abstract: Cold atmospheric plasma is a versatile new tool 
in the biomedical field with applications ranging from 
disinfection, wound healing and tissue regeneration to 
blood coagulation, and cancer treatment. Along with 
improved insights into the underlying physical, chemi-
cal and biological principles, plasma medicine has also 
made important advances in the introduction into the 
clinic. However, in the absence of a standard plasma 
‘dose’ definition, the diversity of the field poses certain 
difficulties in terms of comparability of plasma devices, 
treatment parameters and resulting biological effects, 
particularly with regards to the question of what consti-
tutes a safe plasma application. Data from various in vitro 
cytotoxic and genotoxic studies along with in vivo find-
ings from animal and human trials are reviewed to pro-
vide an overview of the current state of knowledge on the 
safety of plasma for biological applications. Treatment 
parameters employed in clinical studies were well toler-
ated but intense treatment conditions can also induce 
tissue damage or genotoxicity. There is a need identified 
to establish both guidelines and safety limits that ensure 
an absence of (long-term) side effects and to define treat-
ments as safe for applications, where cell stimulation is 
desired, e.g. in wound healing, or those aimed at induc-
ing cell death in the treatment of cancer.
Keywords: cold atmospheric plasma; cytotoxicity; 
mutagenicity.
Introduction
Plasma medicine has rapidly evolved as a field of its own 
over the past years with experience in the clinic now 
spanning a decade (Weltmann and von Woedtke, 2017). 
Research covers a broad range of applications including 
disinfection, wound healing, blood coagulation, tissue 
regeneration or cancer treatment in the medical field 
(Kong et  al., 2009). Another complete sector has devel-
oped around the uses of plasma in food and agriculture 
involving reduction of microbial and chemical contami-
nation, pest control and growth promotion (Bourke et al., 
2018).
The vast potential for biological applications of the 
‘4th state of matter’ lies in the array of reactive species – 
ions, electrons, radicals, charged particles, metastables – 
generated as a gas becomes ionised, with temperatures of 
non-thermal or cold atmospheric plasma (CAP) at close to 
ambient temperature, thus allowing applications on heat-
sensitive biological matter such as tissue (Laroussi, 2018). 
In particular, the formation of reactive oxygen and nitro-
gen species (ROS/RNS) such as ozone, atomic oxygen, 
superoxide anion, hydroxyl radical, hydrogen peroxide, 
nitric oxide and peroxynitrite (Graves, 2012) formed when 
plasma discharge occurs in or with air is biologically rele-
vant, as many of these are involved in biological signalling 
pathways or serve as second messengers. Atmospheric 
cold plasmas may be generated by a range of different 
plasma devices such as plasma jets, plasma torches, 
 di-electric barrier discharge (DBD), floating electrode 
 di-electric barrier discharge (FE-DBD), surface micro-
barrier discharge (SMD), microwave discharge, corona 
discharge or gliding arc and various device conformations 
operating with different working gas compositions or 
input powers have been applied for biomedical investiga-
tions (von Woedtke et al., 2013). Table 1 provides an over-
view of plasma device types most commonly employed in 
plasma medicine and reference to the working principle. 
The discovery that longer-lasting reactive species gener-
ated in a liquid when it is exposed to plasma discharge 
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can mediate similar biological effects in cells and tissues 
as direct exposure to the plasma itself has added another 
dimension to plasma applications, referred to as plasma-
treated or plasma-activated liquids (PAL), with potential 
advantages in storability, transportability and mode of 
application (Mohades et al., 2015).
Extensive knowledge is emerging on the physics of 
the plasma discharge of different plasma devices, on the 
resulting reactive species chemistry at the biological inter-
face and on the translation into various biological effects. 
However, comparability and conclusions across the field 
can be complicated by the vast range of different devices 
in use – many of which are custom-built – and subsequent 
differences between their chemical and biological effec-
tors and effects.
Discussions are ongoing on how best to define a 
‘plasma dose’ or whether such a quantitative defini-
tion will ever be possible in the field of plasma, con-
sidering the multitude of plasma devices and treatment 
parameters, and efforts are being made to establish ref-
erence methods and systems in order to enable compari-
son across devices and treatment protocols. Depending 
on the exposure or treatment intensity, which are 
influenced by plasma device, treatment and target 
parameters, plasma can have cell stimulatory or cell 
inhibitory effects or induce sub-lethal cellular damage 
(Figure 1), a principle similar to the concepts of ‘oxida-
tive eustress’ promoting physiological and ‘oxidative dis-
tress’ causing pathophysiological signalling proposed in 
redox biology (Sies, 2018). The question whether plasma 
exposure is safe, particularly with regards to cell toxic, 
immunogenic or sensitising side effects or genotoxic-
ity and therefore carcinogenic potential, has been key 
for applications in medicine and healthcare but also for 
implementations of plasma technology across food and 
agricultural sectors.
The following review aims to provide an overview of 
findings to date on the safety of plasma treatment based 
on available in vitro and in vivo data. The range of appli-
cations of cold atmospheric plasma in the biomedical 
field and their efficacies have been discussed in detail 
elsewhere (Weltmann and von Woedtke, 2017) and we 
therefore focus only on those aspects of studies pertain-
ing to safety implications. By highlighting experimental 
differences and particularities of various approaches and 
methodologies, this analysis aims to reconcile appar-
ent conflicting experimental outcomes and conclusions 
between some studies, as well as provide a broader picture 
of the current state of knowledge towards safe implemen-
tations of plasma in medicine.
Biological effects of plasma
Plasma is able to kill cells – an effect that is being exploited 
in a range of applications including its use for the inacti-
vation of microorganisms (Bourke et  al., 2017) or induc-
tion of cell death in cancer cells (Schlegel et  al., 2013). 
The cytotoxic effects of plasma result predominantly from 
reactive species generated in the plasma discharge and 
their subsequent transfer to the liquid environment of the 
target cells.
Figure 1: The balance between cell stimulatory and cell inhibitory 
effects is dependent on the plasma exposure/treatment intensity, 
which is determined by device and treatment parameters, as well as 
characteristics of the target cells and their environment.
Genotoxic effects can occur when DNA damage exceeds or escapes 
the capacity of cellular repair mechanisms at sub-lethal plasma 
treatments.
Table 1: Overview of plasma source types frequently used in plasma medicine with reference to publications describing the plasma set-up 
and discharge principle.
Plasma source Abbreviations Gas Reference
Plasma needle Argon, helium, nitrogen (Stoffels et al., 2002)
Plasma torch Argon, helium (Shimizu et al., 2008)
Plasma Jet, atmospheric pressure plasma jet APPJ Argon, helium (with or without other admixtures) (Winter et al., 2015)
Dielectric barrier discharge DBD Air (Brandenburg, 2017)
Floating electrode dielectric barrier discharge FE-DBD Air (Fridman et al., 2006)
Surface micro-barrier discharge SMD Air (Klämpfl et al., 2012)
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ROS/RNS formed in the plasma discharge or adminis-
tered to the cellular environment through plasma activated 
liquids can result in increased oxidative stress in the cells. 
While many of these species are involved in the regula-
tion of normal cellular mechanisms, their concentrations 
are tightly regulated through antioxidants, scavengers 
and detoxifying enzymes as excessive amounts result in 
cellular damage and can cause cell death (Görlach et al., 
2015). Oxidative stress has been linked to the develop-
ment of diseases such as cancer, diabetes or cardiovascu-
lar disease and many chronic inflammatory disorders are 
characterised by elevated levels of intracellular oxidative 
stress (Pisoschi and Pop, 2015).
The effects of plasma on the molecular building 
blocks of cells include changes in protein structure 
(Sakudo et al., 2013), oxidation of lipids (Tero et al., 2016), 
and denaturation of nucleic acids (Arjunan et al., 2015). 
The susceptibility of amino acids to plasma-induced 
modification depends on the amino acid side chains 
with sulfur-containing (cysteine and methionine) and 
aromatic amino acids being particularly sensitive to 
plasma treatment (Takai et al., 2014). Plasma treatment 
can result in changes to protein secondary and tertiary 
structure and loss of protein/enzyme function (Zhang 
et  al., 2015a). The lipid bilayer of the cell membrane is 
particularly susceptible to oxidation by plasma derived 
ROS and can lead to the formation of pores in the cell 
membrane (Van der Paal et al., 2016). Damage to a cell’s 
genetic material can have profound effects on cell pro-
liferation and transcription mechanisms, where faulty 
processes can result in the generation of proteins and 
ultimately cells with altered function, factors which also 
play a role in carcinogenesis. A range of cell cycle check-
points prevent the progression of cell division prior to 
the correction of erroneous genetic material and an ina-
bility to repair the damage can result in the induction of 
the apoptotic pathway leading to programmed cell death 
and the elimination of the cell.
Genotoxicity
DNA damage
The ability of plasma reactive species to induce damage 
in DNA molecules has been shown in a number of studies 
using different types of plasma devices, treatment para-
meters and gas types.
Plasmid DNA solution treated directly with differ-
ent helium plasma jets for 10–60  s showed single and 
double strand breaks with increasing treatment times 
and percentage of oxygen admixture indicating that the 
reactive species produced in the plasma plume were able 
to directly damage DNA material (Ptasinska et al., 2010; 
Alkawareek et  al., 2014). Ptasinska and colleagues esti-
mated that DNA strand-scission induced in plasmid DNA 
by a helium plasma jet was predominantly caused by 
excited and reactive species (>60%) with electrons, posi-
tive ions and UV radiation playing minor roles (Ptasinska 
et al., 2010). Whether short-lived reactive species are able 
to reach nuclear material and directly effect DNA damage 
inside a cell is a matter of debate due to the limited pen-
etration depth and lifespan of many of these species on 
the one hand and their possible reaction with other cellu-
lar components (cell membrane, endoplasmic reticulum 
(ER), mitochondria, antioxidants) encountered as they 
traverse the cell interior on the other. Yet, some plasma 
ROS have shown substantial penetration depth (Szili 
et  al., 2014) and longer lived secondary reactive species 
or products of local reactions such as lipid peroxidation 
may reach the nucleic acids and result in genetic damage.
Plasma has in fact been used as a potent mutagenesis 
tool in bacteria for the generation of microbial mutant 
libraries and may find application as a breeding platform 
for the bioengineering of industrial microbial strains 
(Zhang et al., 2014). Quantitative evaluation of the muta-
tion rate of a plasma based mutagenesis tool compared 
to three conventional mutagenesis systems – ultraviolet 
radiation (90 μW/m2, 5–15  min), 4-nitroquinoline-1-ox-
ide (4-NQO) (0.2–1.0 μg/ml), and N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG) (10–30 μg/ml) – showed that 
the plasma system (helium plasma torch, 10 slm) used at 
30–105 s caused greater DNA damage and higher mutation 
rates (Zhang et al., 2015b).
Various different methods have been employed to 
assess DNA damage in both pro- and eukaryotic cells 
in response to their exposure to plasma discharge or to 
plasma-activated liquids, including the comet assay, the 
micronucleus formation assay or the detection of phos-
phorylated histone H2AX (Table 2).
Phosphorylation of histone variant H2AX (to γ-H2AX) 
is seen as an indication of DNA double-strand breaks 
(DSB) and detectable through immunoblotting or immu-
nostaining. An important role of γ-H2AX is believed to be 
the retention of DNA repair factors near the DSB. However, 
a range of other roles independent of DNA damage and 
repair have been found including chromosome inactiva-
tion, cell differentiation and senescence (Turinetto and 
Giachino, 2015), which suggest that phosphorylation is 
not only a sign of DNA DSB. Furthermore, γ-H2AX can be 
also generated during DNA replication, as a consequence 
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of apoptosis, or is found associated with residual DNA 
damage, and it is therefore important to determine the 
kinetics, number, size, and morphology of γ-H2AX-
associated foci (Sharma et al., 2012).
Kim et al. found accumulation of γ-H2AX markers of 
DNA double strand breaks and p53 expression in mouse 
melanoma cells in response to plasma exposure (Kim 
et al., 2010). The expression of γ-H2AX as hallmarks of DNA 
damage was also detected in plasma-treated MCF10A cells 
where further investigations indicated that this damage 
was mediated by neither ozone nor plasma-induced lipid 
peroxidation and subsequent formation of bulky DNA 
adducts (Kalghatgi and Azizkhan-Clifford, 2011; Kalghatgi 
et al., 2012). Investigations on porcine skin treated with a 
FE-DBD device also showed that γ-H2AX increased over 
plasma-exposure time (Wu et al., 2013). Evidence for the 
generation of pre-mutagenic 8-hydroxy-2′-deoxyguanosine 
(8OHdG) lesions, which are widely used as biomarkers for 
oxidative damage and carcinogenesis (Valavanidis et  al., 
2009), and subsequent adaptive DNA repair response were 
detected in human fibroblast and keratinocyte cells in 
response to helium plasma (Tarricone et al., 2012).
The comet assay or single cell gel electrophoresis is 
employed to determine DNA strand breaks through elec-
trophoresis of lysed single cells on a microscope slide, 
with DNA breaks leading to altered migration behaviour 
visible as a ‘comet tail’ (Collins, 2004). The comet assay 
indicated DNA damage in HaCaT cells exposed to a DBD 
plasma system (Blackert et al., 2013) and in mouse leuko-
cytes treated by a helium plasma needle (Morales-Ramírez 
et  al., 2013), where DNA breakage was proportional to 
plasma exposure time, but showed no evidence of damage 
when mucosal cells were treated with the MiniFlatPlaSter 
(Welz et al., 2013).
DNA damage induced by a helium plasma needle was 
assessed in both prokaryotic and eukaryotic cells using 
the chromotest and comet assays, respectively. No geno-
toxic effects were detected in the Escherichia coli model 
while HeLa cells showed increasing DNA breakage with 
treatments from 10  s and complete fragmentation after 
30 s (García-Alcantara et al., 2013).
The in vitro micronucleus assay is a genotoxicity 
assay for the detection of micronuclei in interphase cells 
resulting from chromosome loss or chromosome breakage 
(Fenech, 2000) and forms part of the OECD guidelines for 
testing of chemicals.
Plasma treatment of human brain cancer cells 
between 30 and 240 s with a DBD plasma system showed 
a treatment time dependent increase in micronuclei for-
mation along with loss in cell viability and clonogenicity 
(Kaushik et al., 2012).
In an in vivo system using the hen’s egg test for micro-
nuclei induction (HET-MN) Kluge and co-workers found 
no increase of micronuclei formation in the red blood 
cells of chicken embryos for any plasma treatment time 
between 90  s and 150  s, and 180  s and 300  s using the 
kINPen 09 or kINPen MED plasma systems, respectively, 
and concluded that an application of these argon plasma 
jets did not pose mutagenic risks (Kluge et al., 2016).
A high-throughput image cytometry micronucleus 
assay was developed by Bekeschus and co-workers to 
investigate mutagenic effects of cold atmospheric plasma 
on mouse lymphocytes. Using the kINPen plasma jet, 10 
different feed gas compositions with varying RONS pro-
files were tested at treatment times leading to less than 
50% reduction in cell metabolic activity, and no increase 
of frequency of micronuclei formation was observed in 
any of the conditions (Bekeschus et al., 2018b).
A micronucleus assay was also used by Hong and 
co-workers to investigate the genotoxic effects of argon-
plasma jet treated cell culture medium on WIL2-NS B 
lymphoblastoid cells incubated with the medium for 24 h 
(Hong et al., 2017). Increasing volume fractions of treated 
medium led to elevated levels of necrosis and the occur-
rence of chromosomal damage including micronuclei, 
nucleoplasmic bridge and nuclear bud formation which 
were correlated to the medium’s H2O2 concentrations.
Overall, plasma is capable of causing damage to 
nucleic acids in isolation and in the cellular context. Dif-
ferences in the detection of DNA damage or lack thereof 
(Table 2) can be results of the different plasma devices 
used, differences in treatment parameters, cell targets or 
experimental methodology. Beyond the parameters such 
as input power, gas flow rates (for plasma jets), and treat-
ment times, factors such as the distance between target 
and plasma device, the cell densities used, or their liquid 
environment (medium, buffer) can introduce further vari-
ability, whilst some cell types are inherently more suscep-
tible to the treatment than others.
Functional DNA damage/mutagenicity
Structural DNA damage will not necessarily translate into 
functional phenotypic effects either due to an effective 
DNA repair machinery, occurrence in a non-transcribed 
genetic region or because the damage does not translate 
to changes in protein expression, structure or altered 
function. Should DNA damage exceed cellular repair 
capacities, the induction of the apoptotic pathway leading 
to cell death may be triggered, ensuring that the damage is 
not propagated during future cell divisions. Assays based 
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on phenotypic changes to a cell system such as the HPRT 
assay, clonogenic assays or the AMES bacterial mutagene-
sis test can provide insight into functional manifestations 
of potential DNA damage in response to plasma treatment 
(Table 3). The hypoxanthine phosphoribosyl transferase 
(HPRT) assay, which is an OECD approved method of 
assessing mutagenic potential in mammalian cells, was 
employed by several groups to investigate the effects of 
direct plasma treatment or treatment with plasma treated 
liquids. The assay relies on lack-of-function mutations at 
the HPRT locus resulting in a lack of functional hypox-
anthine phosphoribosyl transferase expression, which 
enables colony formation in the presence of the otherwise 
toxic nucleoside analogue 6-thioguanine (Johnson, 2012).
Plasma treatment applied to V79 cells after removal of 
culture medium using the MiniFlatPlaSter for 30 s–240 s 
or repeated treatments of 30 s every 12 h for 5 days did not 
induce mutagenicity at the HPRT locus beyond naturally 
occurring spontaneous mutations (Boxhammer et  al., 
2013).
Boehm and co-workers found increased mutation 
rates upon prolonged continuous exposure of CHO-K1 
cells to plasma activated foetal bovine serum (FBS) or 
plasma activated PBS over a time period of 6 weeks, where 
cells were supplemented at every sub-culturing with 10% 
of FBS (or PBS) which had been treated with a DBD source 
for 0, 1, 5 or 10 min (Boehm et al., 2016).
Wende et al. performed a detailed mutagenicity study 
of the kINPen plasma jet using micronuclei testing of 
HaCaT cells exposed to direct plasma exposure, colony 
forming assays of SK-MEL-147, HaCaT, and MRC5 cells after 
2 h exposure to plasma-treated medium and HPRT assay 
of V79 cells exposed to plasma-treated medium for 1  h. 
None of these assays indicated an increased mutagenic 
potential in response to the direct or indirect plasma treat-
ments (Wende et al., 2016).
The safety of the MicroPlaster β plasma torch was 
also assessed using V79  hamster cells, where confluent 
cells were treated for 2, 5 or 10 min in a single treatment 
or for 2  min every day for five consecutive days. Cells 
were covered by PBS for the treatment with subsequent 
medium replacement. No significant increase in mutation 
rate was recorded for any of the treatment times while 
control UVC treatment at 0.01 J/cm2 showed a more than 
3-fold increase of mutations compared to controls (Maisch 
et al., 2017).
Of these four studies employing the HPRT assay, only 
one observed increases in the mutation rate in response 
to plasma activated liquids. Besides some variances in 
methodology, the most important difference was the con-
tinuous exposure of cells to plasma-treated liquids over 
a duration of 3–39 days while the other studies assessed 
once off or repeat exposure of limited duration of either 
direct plasma exposure or plasma activated medium with 
subsequent change of culture medium and hence removal 
of plasma reactive species. This specific study therefore 
presents an excessive treatment regime exposing cells to 
continuous oxidative stress and is thus more likely to gen-
erate DNA damage over time and to exceed the stressed 
cells’ ability for DNA repair. In a similar way, continuous 
exposure to H2O2 in the concentration range detected in 
the plasma activated liquids increased mutations at the 
HPRT locus, indicative of the ability of hydrogen perox-
ide to induce single and double-strand DNA breaks, and 
which has been shown to induce mutations in other HPRT 
models (Ziegler-Skylakakis and Andrae, 1987; Diaz-Llera 
et al., 2000).
While the potential of plasma to induce DNA damage 
such as double strand-breaks has been established, a 
lack of manifestation of such DNA damage in some cell 
systems suggests that the cellular repair machinery may 
be well capable of dealing with such damage when occur-
ring at low rate, as would occur with other effectors.
Key factors influencing the scale of damage are likely 
to be the duration of exposure to plasma or plasma-
treated liquid, the removal of plasma-reactive species 
Table 3: Investigation of functional genetic damage.
Plasma source (working gas) exposure Cell type Assay type Evidence of 
genetic damage
Reference
MiniFlatPlaSter (air) 30–240 s, 30 s every 12 h 
for 5 days
V79 HPRT N (Boxhammer et al., 
2013)
DBD (air) Plasma-treated FBS 10%, 
continuous 3–39 days
CHO-K1 HPRT Y (Boehm et al., 2016)
Argon plasma jet (kINPen) (Ar) Plasma-treated RPMI, 1 h V79 HPRT N (Wende et al., 2016)
MicroPlaster β (Ar) 2–10 min, 5 × 2 min V79 HPRT N (Maisch et al., 2017)
Argon plasma jet (kINPen) (Ar) Plasma-treated medium, 2 h MRC5, HaCat, 
SK-Mel-147
Clonogenic 
assay
N (Wende et al., 2016)
HPRT, hypoxanthine phosphoribosyl transferase assay; DBD, dielectric barrier discharge; FBS, foetal bovine serum.
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post-treatment, as well as the liquid environment of the 
cells as certain antioxidant media components can provide 
cell protective effects (Adachi et al., 2014). However, cases 
where the cellular repair machinery has limited func-
tionality or where the appropriate cell cycle check-points 
are dysfunctional should be analysed in greater detail as 
these may be more prone to mutagenic effects.
Cytotoxicity
Direct plasma treatment or the exposure to plasma acti-
vated liquids can inhibit cell metabolic activity, reduce 
cell proliferation and decrease viability in a wide range 
of mammalian cells (Kalghatgi et  al., 2011). Hydro-
gen peroxide has been shown to be a major, albeit not 
sole, effector of these cytotoxic effects, with cytotoxic-
ity showing dose-response to the concentration of H2O2 
detected in the cell environment (Winter et  al., 2014; 
Boehm et al., 2017).
Plasma generated RONS lead to increases in intracel-
lular oxidative stress, loss of mitochondrial membrane 
potential, caspase activation, cell cycle arrest, apoptosis, 
senescence or necrosis (Hirst et al., 2016). Such processes 
are important in the application of plasmas to the cells 
of living tissues, as they present either unwanted effects 
in wound healing or disinfection applications or indeed 
desired effects in cancer treatment.
Extensive work has been performed particularly on 
the effects of plasma on skin cells such as keratinocytes or 
fibroblasts in light of the range of applications in dermatol-
ogy. Plasma treatments at short treatment times particu-
larly on dermal cell types have shown no cell inhibitory 
effects but were able to stimulate cell migration and wound 
healing (Arndt et al., 2013). Plasma exposure was further-
more shown to affect gene expression, particularly the dif-
ferential regulation of cytokine and chemokine molecules 
such as interleukins and growth factors, involved in wound 
healing both in vivo and in vitro (Arndt et al., 2013, 2015). 
A large range of different plasma devices have been tested 
for dermatological applications (reviewed in Gay-Mim-
brera et al., 2016) using in vitro and in vivo models. Studies 
using topical application of plasma in ex vivo cell or tissue 
models suggested good tissue tolerability at the plasma 
doses and exposure times needed to achieve microbial 
reduction and/or improve wound healing.
Selectivity
In contrast to applications in wound healing, the use of 
plasma reactive species to kill cancerous cells is aimed 
at inducing cell toxic phenomena – DNA damage, loss 
of mitochondrial membrane potential, cell cycle arrest, 
apoptosis or necrosis (Schlegel et  al., 2013). A selectivity 
of plasma for affecting cancerous cells over normal has 
been found in some studies (Keidar et  al., 2011; Tanaka 
et al., 2011; Song et al., 2014; Kim and Chung, 2016) while 
others reported higher resistance or comparable sensitivity 
of malignant cells (Hirst et  al., 2015; Dezest et  al., 2017). 
Increased sensitivity of cancerous cells to plasma redox 
species could be linked to their elevated metabolic activity 
(Hirst et al., 2016) or a higher percentage of actively divid-
ing cells (Schlegel et al., 2013) and thus bears similarities in 
mechanism of action to other cancer therapeutics such as 
certain chemo- or radiotherapies involving an increase in 
oxidative stress (Hirst et al., 2016). A further theory points 
to the higher expression of aquaporins on the cell mem-
brane of cancerous cells as cause for the selective toxicity, 
where these membrane channels enable greater influx of 
ROS such as H2O2 (Yan et al., 2015). An advantage of non-
thermal plasma in cancer treatment could lie in the range 
of generated RONS affecting multiple cellular targets and 
pathways. However, by-stander effects on non-malignant 
surrounding tissues need to be considered and similar to 
side effects observed for radio- and chemotherapy, impacts 
on actively dividing cells could be more pronounced.
Stimulation of the immune system
Recent research focus has turned to the ability of non-
thermal plasma to induce ‘immunogenic cell death’, 
resulting in active recruitment of host immune cells to 
the tumour site and their involvement in tumour cell 
elimination through the recognition of damage associated 
molecular patterns (DAMPs) which are expressed by the 
plasma treated cancer cells (Miller et  al., 2016). Plasma 
treatment has been shown to result in the release of ATP 
(as so-called ‘find me’ signal) and in the localisation of 
calreticulin to the cell-surface in cancer cells (as ‘eat me’ 
signal) (Lin et al., 2015; Bekeschus et al., 2018a). While the 
penetration depths of more stable plasma reactive species 
have been estimated in the μm to mm range (Szili et al., 
2017), immunogenic effects could explain much deeper 
penetration of plasma-induced effects and the reduction 
of subcutaneous tumours. From a safety point of view, 
the immunogenic potential of plasma treatment needs 
to be considered where undesirable immune reactions 
against benign host cells could potentially be triggered or 
 inflammatory responses elicited. A more detailed under-
standing of plasma-induced expression of DAMPs on the 
one hand and the stimulation and migration of immune 
cells on the other will be needed.
Brought to you by | Dublin Institute of Technology
Authenticated
Download Date | 9/13/19 1:57 PM
10      D. Boehm and P. Bourke: Safety of cold plasma
In vivo studies
Animal
Both direct plasma treatment and the use of plasma acti-
vated liquids have been studied in a number of animal, 
and particularly rodent, models and only a selection of 
studies pertinent to plasma tolerability and side effects 
are referenced here.
The MicroPlaster β plasma device was assessed in an in 
vivo wound model in mice with regards to wound healing, 
inflammatory response and cytokine expression. Follow-
ing a 2  min treatment wound healing was accelerated at 
days 3 and 5 post wounding and a range of pro-inflam-
matory cytokines and collagen and alpha-SMA (α smooth 
muscle actin) were upregulated in the dermal tissue while 
no negative side effects such as infection, swelling, oozing 
or erythema were observed (Arndt et al., 2013).
A murine model was also used to determine skin 
sensitisation in response to repeated cold atmospheric 
plasma treatment of 25 s with the kINPen MED device (on 
days 1, 2, 3 and 7). This study showed local short-lasting 
hyperemia in response to the treatment but no longer 
lasting irritation, histological skin damage or other illness 
were detected. The OECD murine local nymph node assay 
protocol indicated no local inflammation as sign of skin 
sensitisation (van der Linde et al., 2017).
Low dose non-thermal plasma of 5 min per day over 
a 4-week period generated with a plasma jet was found to 
accelerate wound healing in a rat model. Treated tissues 
showed increases in 4-HNE (4-hydroxynonenal) and 
E-cadherin but no toxicity to vital organs or significant 
differences in blood markers were observed (Hung et al., 
2016).
Kos and co-workers evaluated the safety of a helium 
plasma jet on mouse skin in vivo for different flow rates of 
1–5 l/min and treatment times of 0.5–4 min using fluores-
cence microscopy, histology and IR measurements (Kos 
et al., 2017). Evidence of both early direct skin damage and 
late indirect skin damage were observed and progressed 
with increasing flow rate and treatment time. Increasing 
flow rates led to increases in surface temperature of up to 
96°C and increases in concentrations of gaseous RONS.
The treatment of both intact and wounded skin of 
pigs using a floating electrode-discharge barrier discharge 
(FE-DBD) at low and high power indicated that at lower 
power (20.4 J/cm2) plasma could be safely applied for up 
to 2 min without inducing microscopic skin damage, while 
wounded skin sustained 5  min of treatment at higher 
power (39 J/cm2) without damage due to protective effects 
of blood clotting (Wu et al., 2013).
An experimental study of cold plasma treatment of 
ulcerative colitis in a mouse model indicated no damage 
to the colon tissue in terms of tissue integrity or histologi-
cal damage following 4  s, 30  s or 60  s treatment with a 
Pin-to-Hole Spark Discharge (PHD) Plasma (Chakravar-
thy et al., 2011). Utsumi and colleagues used plasma acti-
vated medium to treat subcutaneous xenograft tumours of 
ovarian cancer cells in nude mice. Administration of the 
plasma-activated medium via sub-cutaneous injection of 
200 μl was rated as nontoxic by observing mouse weights, 
survival, and behaviour, and no complications such as 
anaphylaxis and skin necrosis were detected (Utsumi 
et al., 2013).
In vivo experiments evaluating the effect of plasma 
treatment on chicken embryos at early and late develop-
mental stages, showed treatments with a DBD device to be 
lethal above 4 min, with higher voltages leading to earlier 
onset of embryonic death and a higher sensitivity of the 
early stage embryos (Zhang et al., 2017).
In light of a predominance of skin-based applica-
tions of cold plasma, a majority of animal model studies 
investigated topical plasma treatments and most of 
these found no adverse effects on the skin tissue or the 
animal in general for different plasma devices and treat-
ments times ranging from several seconds up to 5  min. 
Notable exceptions were skin damage observed by Kos 
et  al. which showed treatment time and gas flow rate 
dependency. This study found local thermal damage to 
be a major contributor to the effects observed whilst most 
other plasma devices have been shown not to increase 
temperatures above 42°C. The lethal effects on chicken 
embryos at treatment times above 4  min (Zhang et  al., 
2017) point to a higher susceptibility of developmental 
processes to plasma reactive species. In summary a range 
of plasma treatments are well tolerated at treatment 
times below 5 min in animal tissues and systemic adverse 
effects have not been observed. Yet sensitivity to longer 
treatments suggests that treatment parameters need to be 
well controlled and monitored as oxidative damage can 
be induced.
Human
A number of clinical studies or patient pilot studies 
have been conducted in the dermatological field where 
plasma is used for microbial reduction and to assist 
wound healing. Most studies to date noted no evidence 
of adverse side effects, sensitisation or allergic reaction 
and suggest that the treatments were well tolerated and 
did not induce relevant side effects (Table 4). A number 
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of clinical studies are furthermore on-going or actively 
recruiting  participants at the current time (https://clini-
caltrials.gov). Most of the studies to date are based on 
three types of plasma devices which have obtained CE 
medical device approval or their precursor devices: the 
MicroPlaSter (Adtec Plasma Technology Co. Ltd., Fuku-
yama, Japan), the kINPen Med (neoplas tools GmbH, 
 Greifswald, Germany), the PlasmaDerm (CYNOGY GmbH, 
Duderstadt, Germany).
MicroPlaSter devices
Isbary and co-workers conducted a number of studies on 
the application of surface micro discharge plasma devices 
(FlatPlaSter2.0, MiniFlatPlaSter, MicroPlaSter alpha, 
MicroPlaSter β) for topical treatment of human skin, 
aimed at microbial reduction and wound healing.
Experiments on ex vivo human skin using the 
FlatPlaSter2.0 and MiniFlatPlaSter devices indicated 
treatments up to 60 s to be safe and tolerable based on his-
tological and imaging analysis (Isbary et al., 2013). Trials 
conducted on in vivo skin showed a 2-min treatment with 
either MicroPlaSter α or MicroPlaSter β plasma devices to 
be a safe, painless and effective technique to decrease the 
bacterial load in chronic wounds of 24 patients without 
occurrence of side-effects (Isbary et al., 2012). The treat-
ments of chronic wounds with a single application of 
3–7  min using the MicroPlaSter α device (Isbary et  al., 
2012) or 5 min weekday treatments of Herpes Zoster with 
the MicroPlaSter β for a total of three to nine treatments 
also indicated no side effects and were well tolerated in all 
cases (Isbary et al., 2014).
Studies by the same group also showed that direct 
and indirect plasma treatment based on surface micro 
barrier discharge compared for decontamination of physi-
ologically contaminated forearms of 12 volunteers demon-
strated good tolerability of the plasma treatment without 
negative side effects including pain, heat or uneasiness 
(Li et al., 2013).
kINPen devices
Investigations of an atmospheric pressure plasma jet and 
a DBD-source on the skin of healthy human volunteers 
showed that plasma was well tolerated in terms of par-
esthesia, pain and heat, without causing damage to the 
skin barrier or resulting in skin dryness (Daeschlein et al., 
2012a,b). In vivo risk assessments of temperature and UV 
exposure by plasma indicated that UV radiation of the 
plasma jet was an order of magnitude below the dose 
inducing sun burn, and that thermal damage of the tissue 
by the plasma could be excluded (Lademann et al., 2009).
No side effects or inflammation were registered in 
trials using the kINPen med for treatment of wounds such 
as chronic leg ulcers (Ulrich et al., 2015) or wound healing 
disorders (Hartwig et al., 2017), or when employed as an 
adjuvant anti-fungal treatment in oral applications (Pre-
issner et al., 2016).
Palliative treatment of advanced, inoperable head 
and neck cancer with the kINPen med was performed in 
six patients by Metelmann et  al. (2018). Reduced odour, 
pain and partial tumour remission was achieved in some 
of the cases with four out of the six patients describing an 
increase in the quality of life while some mild side effects 
such as edema, dry mouth, pain and exhaustion occurred.
PlasmaDerm devices
As outlined above, Daeschlein and coworkers investigat-
ing the effects of both the kINPen plasma jet and a Plasma-
Derm DBD-source on the skin of healthy human volunteers 
found no evidence of skin damage and demonstrated that 
plasma was well tolerated (Daeschlein et  al., 2012a,b). 
PlasmaDerm devices were also employed to study the 
effects of plasma on skin microcirculation as well as anti-
bacterial effects in chronic leg ulcers and were well toler-
ated by the patients without occurrence of pain or adverse 
effects (Brehmer et al., 2015; Kisch et al., 2016a,b).
In summary all studies of topical application of cold 
plasma performed on human patients indicated good tol-
erability and an absence of significant side effects at the 
parameters used.
Long-term studies
In vivo studies of the effects of plasma treatment in the 
long-term or late-stage side effects are scarce to date in 
light of the relative recent evolution of the field and its 
gradual introduction to the clinic. Valuable follow-up data 
would pertain in particular to immunogenic responses, 
sensitisation and possible malignant transformation of 
plasma treated sites as well as the response of cells in 
these areas to a repeated plasma exposure or other stress-
ors such as UV (sunlight) or chemical agents.
A 12-months follow-up study was conducted in five 
patients of laser lesions treated by plasma for 10 s, 30 s 
or three repeated treatments of 10 s and did not show any 
pre-cancerous skin features (Metelmann et al., 2013).
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Schmidt and co-workers performed a detailed 1-year 
follow-up study on mice exposed to 14-day consecutive 
plasma exposure in an ear wound model. Histological, 
biochemical and imaging analysis were used to assess 
long-term side effects of repetitive treatment with the 
argon plasma jet kINPen 11 for 20 s using a total of 84 study 
animals (Schmidt et al., 2017). Plasma treated mice did not 
differ from controls in health state, nutrition or behaviour 
and displayed no chronic wound inflammation or other 
side effects while wound healing progressed physiologi-
cally. Magnetic resonance imaging (MRI) and computer 
tomography/positron emission tomography (CT/PET) 
scans showed no evidence of tumour formation in major 
organs such as liver, lymph node, spleen, heart, lung, and 
brain or at the wound site and the absence of neoplastic 
markers in the blood suggested no other tumour sites.
Though long-term follow-up data is still very limited, 
the available studies indicate no adverse long-term effects 
in either animals or humans and importantly, no evidence 
of tumour formation or pre-cancerous features were 
observed.
Conclusion
In-depth evaluation of clinically relevant plasma-devices 
under conditions currently employed, e.g. for the treat-
ment of wounds, suggests that plasma treatment at these 
conditions is safe and well tolerated. With applications 
having reached the clinic only in the last decade, truly 
long-term clinical follow-up data are still lacking but 
should start to emerge over the next few years. These 
will pertain in particular to the evaluation of potential 
late stage adverse effects, sensitisation and cancerous or 
pre-cancerous progression. Experimental data from more 
excessive, long term or continuous exposure to plasma 
reactive species indicated the potential for a manifestation 
of genotoxic effects, hence, as with any treatment safety 
limits and correct dosage need to be established and will 
be paramount to ensuring patient safety. Potential risks 
for any medical intervention lie in side effects and adverse 
reactions a well as hazards resulting from incorrect, exces-
sive or non-target specific application, or an interaction 
with other drugs and environmental factors. In the case of 
plasma this may pertain in particular to additional sources 
of oxidative stress. Differences in sensitivity of various cell 
and tissue types to plasma have been shown and need to 
be considered in the treatment design.
While a DIN SPEC on ‘General requirements of 
plasma devices in medicine’ was published in an attempt 
to establish a point of reference for the comparison of 
 different devices and their biological effects, there seems 
to be only limited uptake of this reference standard in the 
plasma research community to date (Mann et  al., 2016). 
A lack of comparability therefore remains a major hurdle 
in reconciling what can be conflicting or divergent find-
ings. In the absence of a useful definition of ‘dose’ in the 
plasma context or the establishment of standards, every 
device and treatment regime will need to be assessed indi-
vidually to establish efficacy levels and safety margins 
for the application in question. In light of these limita-
tions, this review does not attempt to draw any overall 
conclusions on the safety of plasma, where the vast array 
of devices, parameters and targets make comparability 
near impossible, but aims to (a) present an overview illus-
trating this complexity and diversity of the field and (b) 
enable readers to identify findings most relevant to their 
own devices and set-up.
While references to mutagenicity or genotoxic-
ity may be seen to fuel ‘plasma-scepticism’ and could 
inhibit implementation of a promising new technology 
in the clinic, open discussions from an early stage can 
help to make the benefit-risk analysis of plasma medi-
cine transparent and support the uptake of this technol-
ogy in the long-run. It is important that all stakeholders 
including endusers are incorporated to this discussion to 
promote successful outcomes and applications. Plasma 
and its derived plasma-activated liquids have immense 
potential across a wide range of applications, however, 
rigorous evaluation along with open discourse and dis-
cussion of its possible risks and limitations are needed 
– not only to ensure a safe implementation but also to 
assist uptake of this novel technology by clinicians, 
healthcare providers and patients and to promote overall 
public acceptance.
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